[Initial experiences in liver scintigraphy in Hodgkin's disease].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to G Curci.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Fibronectin (FN) is a glycoprotein whose plasma concentrations are reduced in many pathological conditions. In patients with hemoblastosis plasma FN was correlated with some clinical and biological parameters (stage of the disease, hepatosplenomegaly, infections and DIC), in order to assess its value as a tumor marker. The results suggest a poor relationship between FN levels and the course of the disease. However, the behaviour of the protein in relation with treatment was dynamic.
Explore the source record for details and available documents.
The Authors report their experience regarding the use of radioisotopes (Hypasults obtained in 40 healthy subjects confirm the reliability of the separate tests. Limitation and value of plasmatic and urinary clearances are briefly discussed. As the methods are simple, reproducible and unharmful for the patient, the Authors suggest an increasing application of these radioisotopic techniques for clinical purposes.
BACKGROUND: Primary non Hodgkin's lymphoma (NHL) of the gastrointestinal tract (GI) is the most frequent extranodal lymphoma accounting for approximately 40% of all extranodal primary NHL. The role of surgery and other treatment modalities in the management of these patients is still controversial. PATIENTS AND METHODS: We reviewed the records of 68 patients with primary GI-NHL. Ten patients had incomplete records and were excluded from further evaluation. The records of 58 patients were considered, and all were available for analysis and follow-up. RESULTS: The most frequent site of involvement was the stomach (47 patients), followed by ileum (7 patients), large bowel (3 patients) and duodenum (1 patient). Malignant lymphomas of follicular center cell origin represented the most prevalent histologic types, accounting for 58% (34 of 58) of all cases. Stage, evaluated according to the criteria of Musshoff, was Ie in 15 cases, IIe in 16, IIIe in 7, and IV in the remaining 20 cases. The median survival for the entire group of 58 patients was 54 months, with 46% of patients surviving at 5 years. The median survival was 71 months for patients in stage I-II, 60 for patients in stage III, and 25 for patients in stage IV (p = 0.016). Moreover, we found significantly improved survival in patients undergoing surgical tumor resection (p = 0.003). CONCLUSIONS: Even if at the present time the optimal management of primary GI-NHL is difficult to assess, our data suggest that it is prudent to advise resection followed by adjuvant CT in most patients, whereas CT alone should be considered only when surgery cannot be performed.
Anemia is a common complication of lymphoproliferative syndromes. The exact pathogenic mechanism of this anemia is unclear. Many patients require progressive and persistent blood transfusions. We treated 10 patients (8 with multiple myeloma, 1 with non Hodgkin Lymphoma, 1 with chronic lymphocytic leukemia) by administering low doses of recombinant human erythropoietin (60 U/kg 3 times a week s.c.). All patients presented anemia with hemoglobin levels less than 10 gr/dl; renal function was not impaired (serum creatinine levels less than 1.2 mg/dl or creatinine clearance greater than 60 ml/min). A response was defined as an increase of hemoglobin level of at least 2 gr/dl or stop of red-cell transfusion within the first 3 months of treatment. Nine patients (90%) responded to treatment with a significant increase in the hemoglobin concentration. Two patients presented a cerebral stroke not correlated with erythropoietin administration.
BACKGROUND: Type II essential cryoglobulinemia may be associated with a lymphoproliferative disorder of beta lineage that shows a low degree of malignancy. METHODS AND RESULTS: The authors report a case recorded of 35 patients (30 females and 5 males) affected by mixed cryoglobulinemia type II (MC II) that has been typed by immunofixation, a procedure that allows the identification of minute amounts of monoclonal components. In 20 patients with the "essential" form, the bone marrow histology revealed the presence of nodular aggregates of lymphocytes that were consistent with the diagnosis of immunocytoma in 14 cases and of early stage plasmocytoma in 1 case. The immunohistochemical analysis carried out in 5 of these cases allowed the identification of B lymphocytes in the nodules, thus confirming the diagnosis of low malignancy lymphoma. In our series the percentage of proliferative disorders of B lymphocyte lineage was 66%. CONCLUSIONS: Our results indicate that the cytohistological analysis of bone marrow is highly recommended in the study of essential mixed cryoglobulinemia and that histological analysis supplemented with immunohistochemistry is preferred to the simple cytological analysis of bone aspirate.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.